News headlines about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OraSure Technologies earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.1626390166935 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the headlines that may have effected Accern’s scoring:

Shares of OraSure Technologies (OSUR) traded up 0.41% during trading on Wednesday, reaching $22.06. The company’s stock had a trading volume of 294,310 shares. OraSure Technologies has a 52 week low of $7.09 and a 52 week high of $23.01. The firm has a market capitalization of $1.31 billion, a P/E ratio of 40.78 and a beta of 1.55. The company has a 50 day moving average price of $21.61 and a 200 day moving average price of $17.35.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.02. The business had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.07 EPS. On average, equities research analysts expect that OraSure Technologies will post $0.48 EPS for the current fiscal year.

A number of analysts have recently commented on the company. Zacks Investment Research downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Canaccord Genuity restated a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 19th. Jefferies Group LLC restated a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 12th. BidaskClub downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, Stephens restated an “overweight” rating and issued a $19.00 target price (up previously from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $18.04.

COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/11/orasure-technologies-osur-given-media-impact-rating-of-0-14.html.

In other news, EVP Anthony Zezzo II sold 72,916 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $21.26, for a total transaction of $1,550,194.16. Following the sale, the executive vice president now owns 218,326 shares of the company’s stock, valued at approximately $4,641,610.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jack E. Jerrett sold 73,463 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $20.77, for a total value of $1,525,826.51. Following the sale, the senior vice president now directly owns 81,593 shares in the company, valued at approximately $1,694,686.61. The disclosure for this sale can be found here. Insiders have sold a total of 717,601 shares of company stock worth $14,977,398 in the last three months. Corporate insiders own 6.40% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.